Emerging drugs for rarer chronic lymphoid leukemias

Expert Opinion on Emerging Drugs

Volumn 13, Issue 1, 2008, Pages 95-118

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chronic lymphocytic leukemia; Emerging drugs; Hairy cell leukemia; Hairy cell leukemia variant; Large granular lymphocyte leukemia; Monoclonal antibodies; Prolymphocytic leukemia; Purine nucleoside analogs; T cell leukemia lymphoma; Therapy

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; AP 23573; ARSENIC TRIOXIDE; CARBOPLATIN; CAT 3888; CAT 8015; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GCR 3888; GCR 8015; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMU 106; INTERFERON; LUMILIXIMAB; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTOSTATIN; PREDNISOLONE; PREDNISONE; PURINE DERIVATIVE; RANIMUSTINE; RAPAMYCIN; RITUXIMAB; ST 152; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE; VINDESINE; ZIDOVUDINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; B CELL LEUKEMIA; CHILL; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DRUG EFFICACY; FEVER; HAIRY CELL LEUKEMIA; HUMAN; HYPOTENSION; INFECTION; LARGE GRANULAR LYMPHOCYTE; LARGE GRANULAR LYMPHOCYTIC LEUKEMIA; LOW DRUG DOSE; MEDLINE; MONOTHERAPY; NAUSEA; PROLYMPHOCYTIC LEUKEMIA; RASH; REVIEW; RIGOR; T CELL LEUKEMIA; T CELL LYMPHOMA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; DRUGS, INVESTIGATIONAL; HUMANS; LEUKEMIA, LYMPHOID;

EID: 41349122271     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.13.1.95     Document Type: Review

References (189)

1. Kroft SH, Finn WG, Peterson LC. The pathology of chronic lymphoid leukemia. Blood Rev 1995;9(4):234-50
2. Ravandi F, O'Brien S. Chronic lymphoid leukemias other than chronic lymphocytic leukemia: diagnosis and treatment. Mayo Clin Proc 2005;80(12):1660-174 • This consise review summarizes recent achievements in biology and treatment of rare chronic lymphoid leukemias.
3. Redaelli A, Laskin BL, Stephens JM, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care 2004;13(3):279-87
4. Jemal A, Siegel R, Ward E, et al. Cancer Stat 2007;57(1):43-66
5. Jaffe ES, Harris N, Stein H, Vardiman JW. Tumours of Hematopoietic and Lymphocid Tissues. World Health Organization Classification of Tumours. Lyon, France: JARC Press; 2001
6. Pettitt AR, Zuzel M, Cawley JC. Hairy cell leukaemia: biology and management. Br J Haematol 1999;106(1):2-8
7. Mey U, Strehl J, Gorschluter M, et al. Advances in the treatment of hairy- cell leukaemia. Lancet Oncol 2003;4(2):86-94 • A comprehensive review of the treatment of hairy cell leukemia.
8. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107(1):265-76
9. Staines A, Cartwright RA. Hairy cell leukaemia: descriptive epidemiology and a case control study. Br J Haematol 1993;85(4):714-7
10. Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia: an update. Curr Opin Hematol 2003;10(4):258-66
11. Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Cur Opin Hematol 2003;10(4):258-66
12. Catovsky D, O'Brien M, Melo JV, et al. Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia. Semin Oncol 1984;11(4):362-9
13. Diez Martin JL, Li CY, Banks PM. Blastic variant of hairy cell leukemia. Am J Clin Pathol 1987;87(5):576-83
14. Hanson CA, Ward PC, Schnitzer B. A multilobular variant of hairy cell leukemia with morphologic similar to T-cell lymphoma. Am J Surg Pathol 1989;13(8):671-9
15. Sun T, Susin M, Shevde N, Telchberg S. Hybrid form of hairy cell leukemia and chronic lymphocytic leukemia. Hematol Oncol 1990;8(5):283-94
16. Cessna MH, Hartung L, Tripp S, et al. Hairy cell leukemia variant: fact or fiction. Am J Clin Pathol 2005;123(1):132-8
17. Robak T. Current treatment options in hairy cell leukemia and hairy cell leukemia variants. Cancer Treat Rev 2006;32(5):365-76 • This comperhesive review presents current treatment strategies in hairy cell leukemia and its variants.
18. Matutes E, Brito-Babapulle V, Dearden C, et al. Prolymphocytosis leukemia of B and T-cell types. Biology and therapy. In: Chronic Lymphoid Leukemias. Cheson ED, editor. New York, Basel, Marcell Dekkeker, Inc.; 2001. p. 325-41
19. Absi A, Hsi E, Kulaycio M. Prolymphocytic leukaemia. Curr Treat Options Oncol 2005;6(3):197-208 • A consise review that summarizes recent progress in biology and therapy of prolymphocytic leukaemia.
20. Cao TM, Coutre SE. T-cell prolymphocytic leukemia update and focus on alemtuzumab (Campath-1H). Hematology 2003;8(1):1-6
21. Ravandi F, Kantarjian H, Jones D, et al. Mature T-cell leukemias. Cancer 2005;104(9):1808-18
22. Shvidel L, Shtalrid M, Bassous L, et al. B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course. Leuk Lymphoma 1999;33(1-2):169-79
23. Herher C, Robain M, Davi F, et al. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma 2001;42(5):981-7
24. Dearden CE. T-cell prolymphocytic leukemia. Med Oncol 2006;23(1):17-22
25. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukaemia. Blood 1991;78(12):3269-74
26. Garand R, Goasguen J, Brizard A, et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Br J Haematol 1998;108(2):488-94
27. Wlodarski MW, Schade AE, Maciejewski JP. T-large granular lymphocyte leukemia: current molecular concepts. Hematology 2006;11(4):245-6
28. Alekshun TJ, Sokol L. Diseases of large granular lymphocytes. Cancer Control 2007;14(2):141-50
29. Sokol L, Loughran TPIr. Large granular lymphocyte leukaemia. Oncologist 2006;11(3):263-73 • A comprehensive review of granular lymphocyte leukemia.
30. Lamy T, Loughran TP. Clinical features of large granular lymphocyte leukemia. Semin Hematol 2003;40(3):185-95
31. O'Malley DP. T-cell large granular leukemia and related proliferations. Am J Clin Pathol 2007;127(6):850-9
32. Rose MG, Berliner N. T-cell large granular lymphocyte leukemia. Oncologist 2004;9(3):247-58
33. Tefferi A, Li CY, Witzig TE, et al. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood 1994;84(8):2721-5
34. Lamy T, Loughran. Large granular lymphocyte leukemia. Cancer Control 1998;5(1):25-33
35. Chan WC, Catovsky D, Foucar K, et al. Aggressive NK-cell leukemia. In: Pathology and Genetics of Tumours of the hematopoietic and Lymphoid Tissues, World Health Organization Classification of Tumours. Jaffe ES, Harris NL, Stein H, et al., editors. Volume 3 Lyon, France IARC Press; 2001
36. Yasunaga J, Matsuoku M. Human T-cell leukemia virus type I induces adult T-cell leukemia: from clinical aspects to molecular mechanisms. Cancer Control 2007;14(2):133-40 • A consise review summarizing recent achievements in pathogenesis and clinical management in patients with adult T-cell leukemia/lymphoma.
37. Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977;50(3):481-92
38. Foucar K. Mature T-cell leukemia including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma and Sezary syndrome. Am J Clin Pathol 2007;127(4):496-510
39. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF - supported combination chemotherapy LSG 15, for adult T-cell leukemia lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001;113(2):375-82
40. Robak T, Blasi ka-Morawiec M, Bło ski J, et al. 2-Chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999;62(1):49-56
41. Krishnan B, Matutes E, Dearden C. Prolymphocytic leukemias. Semin Oncol 2006;33(2):257-63
42. Robak T, Robak P. Current treatment options in prolymphocytic leukemia. Med Sci Monit 2007;13(4):RA69-80
43. Robak T, Korycka A, Kasznicki M, et al. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets 2005;5(6):421-44
44. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997;15(7):2667-72
45. Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma 2004;45(2):205-19
46. Castagna L, Sarina B, Todisco E, et al. Allogenic peripheral stem-cell transplantation with reduced intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up. Bone Marrow Transplant 2005;35(2):1225
47. Garderet L, Bittencourt H, Kaliski A, et al. Treatment of T-prolymphocytic leukemia with nonmyeloablative allogenic stem cell transplantation. Eur J Haematol 2001;66(2):137-9
48. Takeuchi M, Tamaoki A, Soda R, Takahashi K. Spontaneous remission of large granular lymphocyte T cell leukemia. Leukemia 1999;13(2):313-4
49. Pandolfi F, Loughran TP Jr, Starkebaum G, et al. Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. Cancer 1990;65(2):341-8
50. Yamasaki R, Miyazaki Y, Moriuchi Y, et al. Small number of HTLV-1 positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma. Leukemia 2007;21(6):1212-7
51. Yamada Y, Tomonaga M. The current status of therapy for adult T-cell leukaemia-lymphoma in Japan. Leuk Lymphoma 2003;44(4):611-8
52. Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: case report and review of the literature. Bone Marrow Transplant 1999;23(1):87-9
53. Kami M, Hamaki T, Miyakoshi S, et al. Allogenic haematopoietic stem cell transplantation for the treatment of adult T cell leukaemia/lymphoma. Br J Haematol 2003;120(2):304-9
54. Gill PS, Harrington WJr, Kaplan MH, et al. Treatment of adult T-cell leukemia/lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995;332(26):1744-8
55. White JD, Wharfe G, Stewart DM, et al. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk Lymphoma 2001;40(3-4):287-94
56. Ahmed S, Rai KR. Interferon in the treatment of hairy cell leukaemia. Best Pract Res Clin Haematol 2003;16(1):69-81
57. Piro LD, Miller WE, Carrera CJ, et al. Hairy cell leukemia. N Engl J Med 1987;317(14):901-2 (Letter)
58. Juliusson G, Heldal D, Hippe E, et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J Clin Oncol 1995;13(4):989-95
59. Robak T, Błasińska-Morawiec M, Krykowski E, et al. 2-Chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 1996;22(1-2):107-11
60. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol 2003;21(5):891-6
61. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy cell leukemia with cladribine: response, toxicity and long-term follow-up. J Clin Oncol 1997;15(3):1138-42
62. Lauria F, Bocchia M, Marotta G, et al. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia is effective and reduces infectious complications. Haematologica 1999;84(1):22-5
63. Robak T, Jamroziak K, Góra-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective randomized, multicenter trial. Blood 2007;109(9):3672-5 •• The first randomized study comparing weekly administration of cladribine with daily administration in previously untreated patients with hairy cel leukemia.
64. Spiers AS, Parekh SJ, Bishop MB. Hairy cell leukemia: induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol 1984;2(12):1336-42
65. Spiers AS, Moore D, Cassileth PA, et al. Remissions in hairy cell leukemia with pentostatin (2′-deoxycoformycin). N Engl J Med 1987;316(14):825-30
66. Flinn IW, Kopecky KJ, Foucar MK, et al. Long-term follow-up of remission duration, mortality and second malignancies in hairy cell leukemia: patients treated with pentostatin. Blood 2000;96(9):2981-6
67. Else M, Ruchlemer R, Osuji N, et al. Long remission in hairy cell leukemia with purine analogs: report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104(11):2442-8 • Recent study that reported large number of patients treated with pentostatin or cladribine with long follow-up.
68. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia 2001;15(1):184-6
69. Tetreault SA, Roobins BA, Saven A. Treatment of hairy cell leukemia-variant with cladribine. Leuk Lymphoma 1999;35(3-4):347-54
70. Kantarjian HM, Childs C, O'Brien S, et al. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med 1991;90(2):223-8
71. Saven A, Lee T, Schlutz M, et al. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia. J Clin Oncol 1997;15(1):37-43
72. Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994;12(12):2588-93
73. Osuji N, Matutes E, Wotherspoon A, Catovsky D. Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment. Leuk Res 2005;29(2):225-8
74. Loughran TPJr, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994;84(7):2164-70
75. Osuji N, Matutes E, Tjounfjoral G, et al. T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer 2006;107(3):570-8
76. Hamidou MA, Sadr FB, Larny T, et al. Low- dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis. Am J Med 2000;108(9):730-2
77. Sood R, Stewart CC, Aplan PD, et al. Neutropenia associated with T-cell large granular lymphocyte leukemia: long- term response to cyclosporine therapy despite persistence of abnormal cells. Blood 1998;91(9):3372-8
78. Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994;12(12):2588-93
79. Tsirigotis P, Venetis E, Kapsimali V, et al. 2-deoxycoformycin in the treatment of T-large granular lymphocyte leukemia. Leuk Res 2003;27(9):865-7
80. O'Brien S, Kurzrock R, Duvic M, et al. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994;84(3):733-8
81. Sternberg A, Eagleton H, Pillai N, et al. Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity. Br J Haematol 2003;120(4):699-701
82. Taguchi H, Kinoshita KI, Takatsuki K, et al. An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindensine, ranimustine and mitoxantrone with granulocyte colony stimulating factor support. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12(2):186-8
83. Yamada Y, Tomonoga M. The current status of therapy for adult T-cell leukemia - lymphoma in Japan. Leuk Lymphoma 2003;44(4):611-8
84. Tsukasaki K, Fukushima T, Utsunomiya A, et al. Phase III study of VCAP-AMP-VECP vs biweekly CHOP in aggressive adult T-cell leukemia - lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. Blood 2005;106(Suppl 1):239a (Abstract 812)
85. Bazarbachi A, Ghez D, Lepelletier Y, et al. New therapeutic approaches for adult T-cell leukemia. Lancet Oncol 2004;5(11):664-72 • Comperhensive review presenting recent progress in therapy of adult T-cell leukemia/lymphoma.
86. Ogata M, Ogata Y, Imamura T, et al. Successful bone marrow transplantation from an untreated donor in a patient with adult T cell leukemia. Bone Marrow Transplant 2002;30(10):699-701
87. Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27(1):15-20
88. Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood 2005;105(10):4143-5
89. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12(17):5165-73
90. Sokol L, Glass F. T/NK- cell lymphomas/leukemias: Shedding new light on these rare diseases. Cancer Control 2007;14(2):96-7
91. Behera M, Kumar A, Soares HP, et al. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control 2007;14(2):160-6 • Important review presenting current status and future directions in clinical trials of rare diseases.
92. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004;72(2):79-88
93. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non Hodgkin's lymphoma. Drugs 2007;67(3):333-50
94. Campese AF, Bellavia D, Gulino A, et al. Notch signalling at the cross roads of T-cell development and leukemogenesis. Semin Cell Dev Biol 2003;14(2):151-7
95. Smolewski P. Investigating mammalian target of rapamycin inhibitors for their anticancer properties. Expert Opin Investig Drugs 2006;15(10):1201-27
96. Braun T, Carvalho G, Fabre C, et al. Targeting NF-kappa B in hematologic malignancies. Cell Death Differ 2006;13(5):748-58
97. Ruiz S, Krupnik Y, Keating M, et al. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther 2006;5(7):1836-43
98. Satou Y, Nosaka K, Koya Y, et al. Proteasome inhibitor, bortezomib potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004;18(8):1357-63
99. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002;62(4):1083-6
100. Mori N, Matsuda T, Tadano M, et al. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukaemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. J Virol 2004;78(9):4582-90
101. Hermine O, Allard I, Levy V, et al. A prospective Phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002;3(6):276-82
102. Ishitsuka K, Suzumiya J, Aoki M, et al. Therapeutic potential of arsenic trioxide with or without interferon-α for relapsed/refractory adult T-cell leukemia lymphoma. Haematologica 2007;92(5):719-20
103. Maeda Y, Yamaguchi T, Miyataka J, Kanamaru A. Possible therapy with ATRA for adult T-cell leukemia/lymphoma. Nippon Rinsho 2007;65(Suppl 1):719-23
104. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002;20(1):205-13 • An important study evaluating activity and toxicity of alemtuzumab in previously treated patients with prolymphocytic leukemia.
105. Ravandi F, O'Brien S, Jones D, et al. T-cell prolymphocytic leukemia: a single institution experience. Clin Lymphoma Myeloma 2005;6(3):234-9
106. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003;98(4):774-8
107. Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. BioDrugs 2005;19(1):9-22
108. Dearden C, Matutes E, Cazin B, et al. Very high response rates in previously untreated T-cell prolymphocytic leukemia patients receiving alemtuzumab (Campath-1H) therapy. Blood 2003;102(Suppl 1):644a (Abstract 2378)
109. McCune SL, Gockerman JP, Moore JO, et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 2002;43(5):1007-11
110. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98(6):1721-6
111. Chaar BT, Petruska PJ. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Haematol 2007;82(5):417 (Letter)
112. Quigley MM, Bethel KJ, Sharpe RW, Saven A. CD52 expression in hairy cell leukemia. Am J Hematol 2003;74(4):227-30
113. Osuji N, Del Giudice I, Matutes E, et al. CD52 expression in T-cell large granular lymphocyte leukaemia: implications for treatment with alemtuzumab. Leuk Lymphoma 2005;46(5):723-7
114. Rodig SJ, Abramson JS, Pinkus GE, et al. Heterogenous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12(23):7174-9
115. Fietz T, Riger K, Schmittel A, et al. Alemtuzumab (Campath-1H) in hairy cell leukemia relapsing after rituximab treatment. Hematol J 2004;5(5):451-2
116. Osuji N, Wotherspoon A, Catovsky D. Lessons from a case of T-cell large granular lymphocytic leukaemia suggesting that immunomodulatory therapy is more effective than intensive treatment. Leuk Res 2005;29(2):225-8
117. Ru Z, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol 2003;123(2):278-81
118. Rosenblum MD, Labelle JL, Chang CC, et al. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. Blood 2004;103(5):1969-71
119. Onrust SV, Lamb HM, Balfoyr JA. Rituximab. Drugs 1999;58(1):79-88
120. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2005;107(12):4658-62
121. Hagberg H, Lundholm L. Rituximab a chimaeric anti-CD20 monoclonal antibody in the treatment of hairy cell leukaemia. Br J Haematol 2001;115(3):609-11
122. Zinzani PL, Ascani S, Piccaluga PP, et al. Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol 2000;18(22):3875-7
123. Hoffman M, Auerbach L. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol 2000;109(4):900-1
124. Lauria F, Lenoci M, Annino L, et al. Efficacy of anti CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica 2001;86(10):1046-50
125. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102(2):810-3 • The largest study evaluating efficacy and tolerance of rituximab in refractory/relapsed patients with hairy cell leukaemia.
126. Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003;102(12):3906-11
127. Cervetti G, Galimberti S, Andreazzoli F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 2004;73(6):412-7
128. Narat S, Gandla J, Dogan A, Mehta A. Successful treatment of hairy cell leukemia variant with rituximab. Leuk Lymphoma 2005;46(8):1229-32
129. Quach H, Januszewicz H, Westerman D. Complete remission of hairy cell leukemia variant (HCL-v) complicated by red cell aplasia post treatment with rituximab. Haematologica 2005;90(Suppl):ECR26
130. Imamura T, Ohtsuka E, Ogata M, et al. Successful induction of long-term remission using rituximab in a patient with refractory hairy cell leukemia - Japanese variant. Int J Hematol 2004;80(5):432-4
131. Robak T. New agents in chronic lymphocytic leukemia. Curr Treat Options Oncol 2006;7(3):200-12
132. Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Drugs 2007;67(3):333-50
133. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8(2):140-74
134. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002;99(9):3256-62
135. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A Phase I-II study. Blood 2008;111(3):1094-100 •• The first clinical trial of fully human monoclonal antibody ofatumumab in patients with chronic lymphocytic leukemia.
136. Coiffier B, Tilly H, Pedersen LM, et al. Significant correlation between survival endpoints and exposure to ofatumumab (HuMax-CD20) in chronic lymphocytic leukemia. Blood 2006;108(Suppl 1):804a (Abstract 2842)
137. Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106 and its use in combination with the humanized anti-CD22 antibody epratuzumab for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10(8):2868-78
138. Morschhauser F, Leonard JP, Fayad L, et al. Rituximab-relapsing patients with non-Hodgkins lymphoma respond even at lower doses of humanized anti-CD20 antibody, IMMU-106 (hA20): Phase I/II results. Blood 2006;108(Suppl 1):769a (Abstract 2719)
139. Morschhauser F, Leonard JP, Coiffier B, et al. Initial safety and efficacy results of second- generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin's lymphoma. Blood 2005;106(Suppl 1):683a (Abstract 2428)
140. Carnahan J, Stein R, Qu Z, et al. Epratunuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007;44(6):1331-41
141. Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther 2006;6(10):1341-53
142. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21(16):3051-9
143. Strauss SJ, Morschhauser F, Rech J, et al. Multicenter Phase II trial of immunotherapy with the humanized anti CD22 antibody epratuzumab in combination with rituximab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006;24(24):3880-6
144. Byrd JC, O'Brien S, Flinn I, et al. Safety and efficacy results from a Phase I trial of single agent lumiliximab (anti-CD23 antibody) for chronic lymphocytic leukemia. Blood 2004;104(Suppl 1):(Abstract 2503)
145. Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109(11):4655-62
146. Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets 2006;7(10):1301-11
147. Olsen E, Duvic M, Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19(2):376-88
148. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy - resistant hairy - cell leukemia. N Engl J Med 2001;345(4):241-7 •• The first clinical report presenting activity of BL22 immunotoxin in refractory/relapsed classic hairy cell leukemia and its variants.
149. Salvatore G, Beers R, Margulies I, et al. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 2002;8(4):995-1002
150. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv) PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23(27):6719-29
151. Bang S, Nagata S, Onda M, et al. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin Cancer Res 2005;11(4):1545-50
152. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti - Tac (Fv) - PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18(8):1622-36
153. Kreitman RJ, Pastan I. Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol Oncol Clin North Am 2006;20(5):1137-51
154. Morgan SJ, Seymour JF, Prince HM, et al. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clin Cancer Res 2004;10(10):3572-5
155. R) in patients with fludarabine refractory B-cell chronic lymphocytic leukemia Blood 2004;104(Suppl 1):289b (Abstract 4824)
156. Olsen E, Duvic M, Frankel A, et al. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19(2):376-88
157. Robak T, Lech-Mara da E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006;13(26):3165-89 • A comprehensive review of pharmacology and clinical application of purine nucleoside analogues in hematological malignancies.
158. Lech-Mara da E, Korycka A, Robak T. Pharmacological and clinical studies on purine nucleoside analogs - new anticaner agents. Mini Rev Med Chem 2006;6(5):575-81
159. Faderl S, Gandhi V, Keating MJ, et al. The role of clofarabine in hematologic and solid malignancies- development of a next-generation nucleoside analog. Cancer 2005;103(10):1985-95
160. Korycka A, Blo ski JZ, Robak T. Forodesine (BCX-1777, Immucillin H) - a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev Med Chem 2007;7(9):976-83
161. Furman RR, Gore L, Ravandi F, et al. Forodesine IV (Bex-1777) is clinically active in relapsed/refractory T-cell leukemia: results of a Phase II study. (Interim report) Blood 2006;108(Suppl 1):524a (Abstract 1851)
162. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005;23(15):3396-403
163. Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506 U78) in children and young adults with refractory T-cell malignancies: a report from Children's Oncology Group. J Clin Oncol 2005;23(15):3376-82
164. Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics and pharmacodynamics in leukemia cells. J Clin Oncol 2001;19(2):2142-52
165. Lech-Marańda E, Robak E, Korycka A, Robak T. Depsipeptyde (FK 228) as a novel histone deacetylase inhibitor. Mini Rev Med Chem 2007;7(10):1062-9
166. Mann BS, Johnson JR, Cohen MH, et al. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Ocologist 2007;12(10):1247-52
167. Whittaker S, Mcculloch W, Robak T, et al. International multicenter Phase II study of HDAC inhibitor (HDAC) depsipeptide (FK 228) in cutaneous T-cell lymphoma (CFCL) interim analogs. J Clin Oncol 2006;24(Suppl 1):18S (Abstract 3063)
168. Byrd JC, Marcucci G, Parthun MR, et al. A Phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105(3):959-67
169. Nishioka C, Jkezoe T, Yang J, et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappa B. Leuk Res 2007; (E pub ahead of print)
170. Olsen EA, Kim SH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent progressive or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(21):3109-15
171. Costa LJ. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev 2007;33(1):78-84
172. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12(17):5165-73
173. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent tensirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23(23):5347-56
174. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoyl anilide Hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31-9
175. Vink J, Cloos J, Kaspers GJ. Proteasome inhibition as novel treatment strategy in leukaemia. Br J Haematol 2006;134(3):253-62
176. Faderl S, Rai K, Gribben J, et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine - refractory B-cell chronic lymphocytic leukemia. Cancer 2006;107(5):916-24
177. Zinzani PL, Masurac G, Tam M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(27):4293-7
178. Nasr R, El-Sabban ME, Karam JA, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV associated adult T-cell leukemia/lymphoma. Oncogene 2005;24(3):419-30
179. Satou Y, Nosaka K, Koya Y, et al. Proteasome inhibitor bortezomib, potentially inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004;18(8):1357-63
180. Shen L, Au WY, Guo T, et al. Proteasome inhibitor bortezomib induced apoptosis in natural killer (NK) cell leukaemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood 2007;110(1):469-70
181. Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukemia. Lancet Oncol 2006;7(6):480-8
182. Raje N, Anderson KC. Thalidomide and immunonomodulatory drugs as cancer therapy. Curr Opin Oncol 2002;14(6):635-40
183. Chanan-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment - requiring chronic lymphocytic leukemia (CLL). Blood 2005;106(10):3348-52
184. Morotti A, Cilloni D, Parvis G, et al. Thalidomide - induced partial stable remission in a case of refractory progressive B-Cell chronic lymphocytic leukemia. Leuk Res 2007; [Epub ahead of print]
185. Chanan-Khan A, Miller KC, Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a Phase II study. J Clin Oncol 2006;24(34):5343-9
186. Strupp C, Fenk R, Kundgen A, et al. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide. Leuk Res 2005;29(8):967-9
187. Carson DA, Leoni LM. Hairy cell leukemia as a model for drug development. Best Pract Res Clin Haematol 2003;16(1):83-9
188. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997;15(7):2667-72
189. Gillet N, Florins A, Boxus M, et al. Mechanisms of leukenogenesis induced by bovine leukemia virus prospects for novel anti-retroviral therapies in human. Retrovirology 2007;4(18):[10.1186/1742-4690-4-18]